Phase II
The news comes just three weeks after Merck paused its Phase II IMAGINE-DR trial, which was studying a combination of islatravir with MK-8507.
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
An investigational drug for Dravet syndrome is showing promise in treating the progressive form of genetic epilepsy.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
The company plans to move it into Phase III studies in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022.
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
Adagio claims that none of the mutations found in Omicron are linked with escape from ADG20 neutralization in vitro.
Two biopharma companies developing therapeutics in the oncology space begin the week with strong signals in Phase II.
As the late-stage trials continue to progress, Talaris is rapidly ramping up its resources and investments.
Treatment for non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, consists mainly of lifestyle modification – specifically dieting and weight loss.
PRESS RELEASES